GB0326407D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB0326407D0
GB0326407D0 GBGB0326407.4A GB0326407A GB0326407D0 GB 0326407 D0 GB0326407 D0 GB 0326407D0 GB 0326407 A GB0326407 A GB 0326407A GB 0326407 D0 GB0326407 D0 GB 0326407D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0326407.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0326407.4A priority Critical patent/GB0326407D0/en
Publication of GB0326407D0 publication Critical patent/GB0326407D0/en
Priority to BRPI0416285-4A priority patent/BRPI0416285A/pt
Priority to AU2004291296A priority patent/AU2004291296B2/en
Priority to JP2006538791A priority patent/JP2007510692A/ja
Priority to CNA2004800333979A priority patent/CN1878764A/zh
Priority to PL04797809T priority patent/PL1689737T3/pl
Priority to ARP040104145A priority patent/AR046233A1/es
Priority to PT04797809T priority patent/PT1689737E/pt
Priority to US10/595,662 priority patent/US20080262041A1/en
Priority to SI200430872T priority patent/SI1689737T1/sl
Priority to PCT/EP2004/012772 priority patent/WO2005049600A1/en
Priority to MYPI20044708A priority patent/MY138378A/en
Priority to EP04797809A priority patent/EP1689737B1/en
Priority to AT04797809T priority patent/ATE401321T1/de
Priority to DK04797809T priority patent/DK1689737T3/da
Priority to CA002546007A priority patent/CA2546007A1/en
Priority to ES04797809T priority patent/ES2310295T3/es
Priority to RU2006120417/04A priority patent/RU2006120417A/ru
Priority to TW093134192A priority patent/TW200528439A/zh
Priority to KR1020067009274A priority patent/KR20060118477A/ko
Priority to DE602004015144T priority patent/DE602004015144D1/de
Priority to IL175279A priority patent/IL175279A0/en
Priority to MA29020A priority patent/MA28156A1/fr
Priority to IS8477A priority patent/IS8477A/is
Priority to NO20062661A priority patent/NO20062661L/no
Priority to HK07100589A priority patent/HK1094698A1/xx
Priority to CY20081101120T priority patent/CY1108404T1/el
Priority to HR20080501T priority patent/HRP20080501T3/xx
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB0326407.4A 2003-11-12 2003-11-12 Chemical compounds Ceased GB0326407D0 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
GBGB0326407.4A GB0326407D0 (en) 2003-11-12 2003-11-12 Chemical compounds
DE602004015144T DE602004015144D1 (de) 2003-11-12 2004-11-10 Beta-lactame zur behandlung von erkrankungen des zns
EP04797809A EP1689737B1 (en) 2003-11-12 2004-11-10 Beta-lactams for the treatment of cns disorders
DK04797809T DK1689737T3 (da) 2003-11-12 2004-11-10 Beta-lactamer til behandling af sygdomme i CNS
JP2006538791A JP2007510692A (ja) 2003-11-12 2004-11-10 Ｃｎｓ障害の治療のためのベータ−ラクタム
CNA2004800333979A CN1878764A (zh) 2003-11-12 2004-11-10 用于治疗CNS病症的β－内酰胺
PL04797809T PL1689737T3 (pl) 2003-11-12 2004-11-10 Beta-laktamy do leczenia schorzeń OUN
ARP040104145A AR046233A1 (es) 2003-11-12 2004-11-10 Derivados de piperidinillactamas, procedimiento para prepararlos y composicion farmaceutica.
PT04797809T PT1689737E (pt) 2003-11-12 2004-11-10 Beta-lactamas para tratamento de perturbações do snc
US10/595,662 US20080262041A1 (en) 2003-11-12 2004-11-10 Beta-Lactams for Treatment of Cns Disorders
SI200430872T SI1689737T1 (sl) 2003-11-12 2004-11-10 Beta laktami za zdravljenje motenj cĺ˝s-ja
PCT/EP2004/012772 WO2005049600A1 (en) 2003-11-12 2004-11-10 Beta-lactams for treatment of cns disorders
MYPI20044708A MY138378A (en) 2003-11-12 2004-11-10 Lactam derivative
BRPI0416285-4A BRPI0416285A (pt) 2003-11-12 2004-11-10 beta-lactams para o tratamento de distúrbios do snc
AT04797809T ATE401321T1 (de) 2003-11-12 2004-11-10 Beta-lactame zur behandlung von erkrankungen des zns
AU2004291296A AU2004291296B2 (en) 2003-11-12 2004-11-10 Lactams for treatment of CNS disorders
CA002546007A CA2546007A1 (en) 2003-11-12 2004-11-10 Beta-lactams for treatment of cns disorders
ES04797809T ES2310295T3 (es) 2003-11-12 2004-11-10 Beta-lactamas para el tratamiento de trastornos del snc.
RU2006120417/04A RU2006120417A (ru) 2003-11-12 2004-11-10 Бета-лактамы для лечения нарушений цнс
TW093134192A TW200528439A (en) 2003-11-12 2004-11-10 Chemical compounds
KR1020067009274A KR20060118477A (ko) 2003-11-12 2004-11-10 Ｃｎｓ 장애 치료용 베타-락탐
IL175279A IL175279A0 (en) 2003-11-12 2006-04-27 Beta-lactams for treatment of cns disorders
MA29020A MA28156A1 (fr) 2003-11-12 2006-05-11 Beta-lactames pour le traitement de troubles du systeme nerveux central
IS8477A IS8477A (is) 2003-11-12 2006-05-22 Beta-laktöm til að meðhöndla MTK sjúkdóma
NO20062661A NO20062661L (no) 2003-11-12 2006-06-09 Beta-laktamer for behandling av CNS lidelser
HK07100589A HK1094698A1 (en) 2003-11-12 2007-01-24 Beta-lactams for the treatment of cns disorders
CY20081101120T CY1108404T1 (el) 2003-11-12 2008-10-08 Βητα-λακταμες για θεραπεια διαταραχων του κνς
HR20080501T HRP20080501T3 (en) 2003-11-12 2008-10-09 Beta-lactams for the treatment of cns disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0326407.4A GB0326407D0 (en) 2003-11-12 2003-11-12 Chemical compounds

Publications (1)

Publication Number Publication Date
GB0326407D0 true GB0326407D0 (en) 2003-12-17

Family

ID=29726427

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0326407.4A Ceased GB0326407D0 (en) 2003-11-12 2003-11-12 Chemical compounds

Country Status (28)

Country Link
US (1) US20080262041A1 (ko)
EP (1) EP1689737B1 (ko)
JP (1) JP2007510692A (ko)
KR (1) KR20060118477A (ko)
CN (1) CN1878764A (ko)
AR (1) AR046233A1 (ko)
AT (1) ATE401321T1 (ko)
AU (1) AU2004291296B2 (ko)
BR (1) BRPI0416285A (ko)
CA (1) CA2546007A1 (ko)
CY (1) CY1108404T1 (ko)
DE (1) DE602004015144D1 (ko)
DK (1) DK1689737T3 (ko)
ES (1) ES2310295T3 (ko)
GB (1) GB0326407D0 (ko)
HK (1) HK1094698A1 (ko)
HR (1) HRP20080501T3 (ko)
IL (1) IL175279A0 (ko)
IS (1) IS8477A (ko)
MA (1) MA28156A1 (ko)
MY (1) MY138378A (ko)
NO (1) NO20062661L (ko)
PL (1) PL1689737T3 (ko)
PT (1) PT1689737E (ko)
RU (1) RU2006120417A (ko)
SI (1) SI1689737T1 (ko)
TW (1) TW200528439A (ko)
WO (1) WO2005049600A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008009444A (es) * 2006-01-24 2008-10-20 Biosignal Ltd Nuevas lactamas.
AU2015200142B2 (en) * 2006-01-24 2016-07-07 Unilever Plc Novel lactams

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL262366A (ko) * 1960-03-14
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2083891A1 (en) * 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
GB9200535D0 (en) * 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
US5824690A (en) * 1993-05-06 1998-10-20 Hoechst Marion Roussel Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
HU221434B (en) * 1994-08-25 2002-10-28 Merrell Pharma Inc Substituted piperidines, pharmaceutical compositions containing them and their use
US5780466A (en) * 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
US6211199B1 (en) * 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
FR2779429B1 (fr) * 1998-06-03 2000-07-13 Synthelabo Derives d'oxindole, leurs preparations et leurs applications en therapeutique
US6204265B1 (en) * 1998-12-23 2001-03-20 Schering Corporation Substituted oximes and hydrazones as neurokinin antagonists
GB0114867D0 (en) * 2001-06-18 2001-08-08 Merck Sharp & Dohme Therapeutic agents
GB0412865D0 (en) * 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
EP1689737B1 (en) 2008-07-16
MY138378A (en) 2009-05-29
IS8477A (is) 2006-05-22
NO20062661L (no) 2006-06-09
DE602004015144D1 (de) 2008-08-28
TW200528439A (en) 2005-09-01
US20080262041A1 (en) 2008-10-23
SI1689737T1 (sl) 2008-12-31
ATE401321T1 (de) 2008-08-15
AU2004291296A1 (en) 2005-06-02
WO2005049600A1 (en) 2005-06-02
HRP20080501T3 (en) 2008-11-30
CY1108404T1 (el) 2014-02-12
KR20060118477A (ko) 2006-11-23
IL175279A0 (en) 2006-09-05
EP1689737A1 (en) 2006-08-16
PT1689737E (pt) 2008-10-24
PL1689737T3 (pl) 2008-12-31
CN1878764A (zh) 2006-12-13
AU2004291296B2 (en) 2011-04-07
BRPI0416285A (pt) 2007-01-23
MA28156A1 (fr) 2006-09-01
AR046233A1 (es) 2005-11-30
HK1094698A1 (en) 2007-04-04
JP2007510692A (ja) 2007-04-26
CA2546007A1 (en) 2005-06-02
ES2310295T3 (es) 2009-01-01
DK1689737T3 (da) 2008-10-27
RU2006120417A (ru) 2007-12-27

Similar Documents

Publication Publication Date Title
GB0317009D0 (en) Chemical compounds
GB0304194D0 (en) Chemical compounds
GB0308208D0 (en) Chemical compounds
GB0319124D0 (en) Chemical compounds
GB0319126D0 (en) Chemical compounds
GB0311276D0 (en) Chemical compounds
GB0315203D0 (en) Chemical compounds
EP1648448A4 (en) CHEMICAL COMPOUNDS
EP1590339A4 (en) CHEMICAL COMPOUNDS
GB0318422D0 (en) Chemical compounds
EP1654251A4 (en) CHEMICAL COMPOUNDS
GB0308801D0 (en) Chemical compounds
GB0318423D0 (en) Chemical compounds
GB0319690D0 (en) Chemical compounds
GB0306358D0 (en) Chemical compounds
GB0310724D0 (en) Chemical compounds
GB0306357D0 (en) Chemical compounds
GB0314373D0 (en) Chemical compounds
GB0304723D0 (en) Chemical compounds
GB0326407D0 (en) Chemical compounds
GB0314370D0 (en) Chemical compounds
GB0315872D0 (en) Chemical compounds
GB0319149D0 (en) Chemical compounds
GB0302078D0 (en) Chemical compounds
GB0310446D0 (en) Chemical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)